Cue Biopharma Posts $50M Q3 Loss, $57.9M Cash, New CUE-221 Subgroup Data
CUE has more than doubled off its 52-week low of $4.971.
Summary
Cue Biopharma reported a $50.0M Q3 2026 net loss — mostly non-cash stock compensation — with $57.9M in cash, new high-IgE CUE-221 subgroup data, an FDA-cleared food allergy IND and first CUE-401 dosing.
Key Events · Earnings and Guidance · CUE
-
Q3 Loss Driven by Non-Cash Comp
Net loss was $50.0M versus $7.4M a year earlier; G&A rose to $29.8M from $4.9M and R&D to $17.0M from $4.8M, primarily non-cash stock-based compensation from performance-based equity grants made after the Q2 2026 strategic transformation.
-
Cash Position and Runway
Cash and cash equivalents stood at $57.9M as of September 30, 2026, against a $50.0M quarterly net loss that is largely non-cash.
-
High-IgE Subgroup Data Strengthens Case
In patients with baseline IgE ≥300 IU/mL, 78% on 4 mg/kg achieved complete hive resolution (HSS7=0) at week 12 versus 0% on placebo (P<0.005); post-hoc complete response (UAS7=0) was 67% versus 0% (p<0.05).
-
CUE-401 Dosing and Food Allergy IND
First-in-human Phase 1 dosing of CUE-401 is underway in the first cohort, and the FDA has cleared the CUE-221 IND for food allergy.
Analysis · CUE · Life Sciences
The headline number looks ugly — a $50.0M quarterly net loss against a roughly $102M market cap — but most of it is accounting, not cash burn. G&A jumped to $29.8M from $4.9M and R&D to $17.0M from $4.8M, with the bulk of the increase non-cash stock compensation from performance-based equity grants made after the Q2 strategic transformation. On the real cash picture, $57.9M was on hand at September 30, funding the newly dosed CUE-401 Phase 1 and the CUE-221 food allergy program now that its IND is cleared. More important than the P&L is the clinical detail: among patients with high baseline IgE (≥300 IU/mL), 78% on 4 mg/kg hit complete hive resolution at week 12 versus 0% on placebo — the argument for CUE-221 reaching the 20-30% of patients ineligible for XOLAIR. Near-term non-dilutive cash also gets a boost from the $5.5M ImmunoScape receivable, upsized from $5.0M with $3.0M due in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUE was trading at $13.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.4M. The 52-week trading range was $4.97 to $45.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.